10.7 C
London
Sunday, February 23, 2025
HomeMarketsEurope Markets

Europe Markets

spot_img

Rivastigmine Hexal | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP)...

SomaKit TOC | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for SomaKit TOC. It explains how the Agency assessed the medicine to...

Entresto | European Medicines Agency (EMA)

OverviewEntresto is a heart medicine used in adults with chronic (long-term) heart failure who have symptoms of the disease and reduced ejection fraction...

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

Medicines containing semaglutide: PRAC investigating risk of rare eye conditionPRAC will assess risk of non-arteritic anterior ischemic optic neuropathy (NAION)EMA’s safety committee, PRAC,...

Twynsta | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for Twynsta. It explains how the Committee for Medicinal Products for Human...

Pravafenix | European Medicines Agency (EMA)

OverviewPravafenix is used in adults at high risk of heart disease whose low-density-lipoprotein (LDL) cholesterol is already being controlled with pravastatin alone or...

Two new vaccines against bluetongue recommended for approval

EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 to protect sheep against bluetongue disease. Bluevac-3 is also approved...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img